Eli Lilly (NYSE:LLY) reported Phase 3 data showing its oral GLP-1 candidate, orforglipron, produced greater blood sugar and weight reduction in adults with type 2 diabetes than Novo Nordisk’s oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results